Format
Sort by
Items per page

Send to

Choose Destination

Best matches for antiandrogen therapy AND screening for osteoporosis:

Search results

Items: 1 to 20 of 120

1.

Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT).

Chahin R, Gulamhusein H, Breunis H, Alibhai SM.

Support Care Cancer. 2016 Nov;24(11):4713-20. doi: 10.1007/s00520-016-3320-1. Epub 2016 Jul 2.

PMID:
27370648
2.

Primary Care of the Prostate Cancer Survivor.

Noonan EM, Farrell TW.

Am Fam Physician. 2016 May 1;93(9):764-70. Review.

3.

Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy.

Kim SH, Seong do H, Yoon SM, Choi YD, Song Y, Song H, Choi E.

Eur J Oncol Nurs. 2016 Apr;21:197-204. doi: 10.1016/j.ejon.2015.10.004. Epub 2015 Oct 27.

PMID:
26522218
4.
5.

Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.

Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20.

PMID:
25990353
6.

Bone health management in men undergoing ADT: examining enablers and barriers to care.

Damji AN, Bies K, Alibhai SM, Jones JM.

Osteoporos Int. 2015 Mar;26(3):951-9. doi: 10.1007/s00198-014-2997-6. Epub 2014 Dec 20.

PMID:
25526712
7.

Bone health in patients with prostate cancer.

Miñana B, Cózar JM, Alcaraz A, Morote J, Gómez-Veiga FJ, Solsona E, Rodríguez-Antolín A, Carballido J.

Actas Urol Esp. 2014 Dec;38(10):685-93. doi: 10.1016/j.acuro.2014.05.003. Epub 2014 Jun 14. Review. English, Spanish.

PMID:
24934457
8.

Practical guide to bone health in the spectrum of advanced prostate cancer.

Butoescu V, Tombal B.

Can J Urol. 2014 Apr;21(2 Supp 1):84-92. Review.

9.

Bone health care for patients with prostate cancer receiving androgen deprivation therapy.

Tsang DS, Alibhai SM.

Hosp Pract (1995). 2014 Apr;42(2):89-102. doi: 10.3810/hp.2014.04.1107. Review.

PMID:
24769788
10.

The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study.

Nadler M, Alibhai S, Catton P, Catton C, Jones J.

Support Care Cancer. 2014 Sep;22(9):2409-15. doi: 10.1007/s00520-014-2183-6. Epub 2014 Apr 3.

PMID:
24696083
11.

Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.

Planas Morin J, Celma Domenech A, Placer Santos J, Trilla Herrera E, Salvador Lacambra C, Lorente Garcia D, Regis L, Carles Galceran J, Morote Robles J.

Rheumatol Int. 2014 Oct;34(10):1419-25. doi: 10.1007/s00296-014-2977-3. Epub 2014 Mar 11.

PMID:
24615021
12.

Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.

Suarez-Almazor ME, Peddi P, Luo R, Nguyen HT, Elting LS.

Support Care Cancer. 2014 Feb;22(2):537-44. doi: 10.1007/s00520-013-2008-z. Epub 2013 Oct 22.

13.

Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.

Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E, Jenkins T, Hamilton EJ, Bate K, Chan I, Zajac JD, Grossmann M.

Andrology. 2013 Jul;1(4):583-9. doi: 10.1111/j.2047-2927.2013.00093.x. Epub 2013 May 20.

14.

Locally advanced prostate cancer: effective treatments, but many adverse effects.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Review.

PMID:
23367679
15.

Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer.

Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM.

BJU Int. 2013 Jun;111(8):1301-9. doi: 10.1111/j.1464-410X.2012.11777.x. Epub 2013 Jan 25.

16.

Low rate of bone density testing in men receiving androgen deprivation therapy.

Barton MK.

CA Cancer J Clin. 2013 Mar-Apr;63(2):85-6. doi: 10.3322/caac.21176. Epub 2013 Jan 14. No abstract available.

17.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2013 Jan;189(1 Suppl):S34-42; discussion S43-4. doi: 10.1016/j.juro.2012.11.017. Review.

PMID:
23234628
18.

[Androgen deprivation therapy for prostate cancer and osteoporotic risk].

Cortet B, Lartigau E, Caty A, Moulinier F, Staerman F, Villamizar-Vesga J, Villers A.

Prog Urol. 2012 Sep;22 Suppl 2:S31-8. doi: 10.1016/S1166-7087(12)70034-9. French.

PMID:
23098788
19.
20.

Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.

Greenspan SL, Wagner J, Nelson JB, Perera S, Britton C, Resnick NM.

J Bone Miner Res. 2013 Feb;28(2):325-32. doi: 10.1002/jbmr.1771.

Supplemental Content

Loading ...
Support Center